Completed PHASE2 INTERVENTIONAL NCT00193297

Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma

A Phase II Study of a Three-Day Schedule of Topotecan Plus Paclitaxel and Carboplatin on Day Three in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma

Sponsor: GlaxoSmithKline

Conditions Ovary Cancer

Interventions Carboplatin Paclitaxel Topotecan

Updated 6 times since 2017 Last updated: May 2, 2011 Started: Feb 28, 2002 Primary completion: Jun 30, 2005 Completion: Jun 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ovary Cancer, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 6 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
SCRI Development Innovations, LLC

Data source: SCRI Development Innovations, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.